Santen Pharmaceutical Co (SZD0) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Stn1013800 Ophthalmic Solution | Blepharoptosis | earlyPhase1 | Completed | A Pharmacokinetics (PK) Study in Healthy Adults | Mar 11, 2025 | ― |
| Stn1013800 Ophthalmic Solution, Stn1013800 Ophthalmic Solution Liquid Base, Without Stn1013800 | Blepharoptosis | Phase III | Recruiting | A Study in Chinese Patients With Acquired Blepharoptosis | Nov 08, 2024 | ― |
| Latanoprost, De-117B Eye Drops | Ocular Hypertension, Open Angle Glaucoma | Phase III | Recruiting | A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Oct 29, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Stn1013800 Ophthalmic Solution | earlyPhase1 | Blepharoptosis | Completed | A Pharmacokinetics (PK) Study in Healthy Adults | Mar 11, 2025 | ― |
| Stn1013800 Ophthalmic Solution, Stn1013800 Ophthalmic Solution Liquid Base, Without Stn1013800 | Phase III | Blepharoptosis | Recruiting | A Study in Chinese Patients With Acquired Blepharoptosis | Nov 08, 2024 | ― |
| Latanoprost, De-117B Eye Drops | Phase III | Ocular Hypertension, Open Angle Glaucoma | Recruiting | A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Oct 29, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Santen Pharmaceutical (DE:SZD0) have in its pipeline
Santen Pharmaceutical Co DE:SZD0 is currently developing the following drugs: Stn1013800 Ophthalmic Solution, Stn1013800 Ophthalmic Solution, Stn1013800 Ophthalmic Solution Liquid Base, Without Stn1013800, Latanoprost, De-117B Eye Drops. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
